179 volunteer for COVID vaccine in Belagavi

Photo of author

Zydus Cadila has launched Phase II clinical trials of its Covid-19 vaccine candidate, ZyCoV-D, which showed promise in a Phase I study.

175 volunteers from Belagavi have participated in the phase 2 of the study.

The company completed dosing in the Phase I trial, where the vaccine was found to be safe and well tolerated in healthy participants.

Covaxin developed by Bharat Biotech, Hyderabad has commended its Human clinical trials phase 1 were done on 4 volunteers.

Both the trials are been undergoing in association with Indian Council of Medical Research (ICMR) at Jeevan Rekha Hospital in Belagavi.

jeevan-rekha covaxin

Phase 2 of Covaxin has also commenced now.

Phase II clinical trials of ZyCoV-D is for evaluating the safety and immunogenicity of the vaccine in a larger population.

ZyCoV-D is a plasmid DNA vaccine candidate. When delivered into the host cells, the plasmid DNA is known to translate into the viral protein and trigger a strong cellular and humoral immune response.

Leave a Comment